Sector: Healthcare | Industry: Healthcare Facilities & Services |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4978 Santa Anita Ave Ste 205 TEMPLE CITY CA 91780-3600 |
Tel: | 1-415-2172633 |
Website: | https://www.fulgentgenetics.com |
IR: | See website |
Key People | ||
Ming Hsieh Chairman of the Board, President, Chief Executive Officer | Paul Kim Chief Financial Officer | Jian Xie Chief Operating Officer | Han Lin Gao Chief Scientific Officer, Laboratory Director |
Business Overview |
Fulgent Genetics, Inc. is a technology company, which offers COVID-19 testing services, molecular diagnostic testing services and comprehensive genetic testing designed to provide physicians and patients with clinically actionable diagnostic information to improve the patient care quality. The Company develops a technology platform, which offers a test menu. It performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels. Its test offerings also include Solid Tumor Molecular Profiling for somatic cancer testing, Rapid Whole Genome testing developed for children in neonatal intensive care units or pediatric intensive care units its Newborn Genetic Analysis panel, and a single front-line test designed to comprehensively detect ataxia-related variants. It also offers certain research service tests, which are ordered by research institutions and other similar institutional customers. |
Financial Overview |
For the nine months ended 30 September 2022, Fulgent Genetics Inc revenues decreased 26% to $551.3M. Net income decreased 59% to $167.2M. Revenues reflect Insurance segment decrease of 41% to $236.3M, Institutional segment decrease of 7% to $314.2M. Net income also reflects General and administrative increase from $26.3M to $76.1M (expense), Selling and marketing increase of 76% to $25.5M (expense). |
Employees: | 645 as of Feb 1, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $453.29M as of Sep 30, 2022 |
Annual revenue (TTM): | $802.94M as of Sep 30, 2022 |
EBITDA (TTM): | $395.32M as of Sep 30, 2022 |
Net annual income (TTM): | $271.57M as of Sep 30, 2022 |
Free cash flow (TTM): | $277.33M as of Sep 30, 2022 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 29,438,052 as of Nov 1, 2022 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |